Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541225 · ClinicalTrials.gov registry record · Phase 1
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
A Phase 1 study, sponsored by Nuvation Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT04541225 is a Phase 1 study that was terminated before completion, run by Nuvation Bio. The registered enrollment target is 74 participants.
The verdict
NCT04541225, a Phase 1 study, was terminated before completion, sponsored by Nuvation Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422. The study population comprised adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and without brain metastases, and recurrent or refractory metastatic castration-resistant prostate cancer (mCRPC). All patients self-administered NUV-422 orally in 28-day cycles until disease progression, toxicity, withdrawal of consent, or termination of the study.
Interventions
- DRUG NUV-422
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2020-12-08 |
| Est. Completion | 2022-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04541225
The ClinicalTrials.gov registry entry for NCT04541225 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuvation Bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NUV-422 is the first listed.
NCT04541225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04541225 about?
NCT04541225 is a clinical study titled "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors". At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422. The study population comprised adults with recurrent or refractory high-grade gliomas (HGGs), metastatic breast cancer (mBC), with and...
What is the current status of trial NCT04541225?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2020-12-08. Estimated completion is 2022-08-31.
What interventions are being tested in trial NCT04541225?
The interventions under investigation include: NUV-422 (DRUG).
Who is sponsoring clinical trial NCT04541225?
This trial is sponsored by Nuvation Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.